Modified Folfox6 With Or Without Radiation In Neoadjuvant Treatment Of Locally Advanced Rectal Cancer: Final Results Of The Chinese Fowarc Multicenter Randomized Trial.

3502Background: The FOWARC trial compared FOLFOX6 with or without Radiation in neoadjuvant treatment of locally advanced rectal cancer to 5-FU chemoradiotherapy. First results of early secondary endpoints have been published (Deng et al., JCO 2016). Here we present the primary endpoint, disease-free survival (DFS) at 3 years. Methods: Between 01/2011-02/2015, patients with rectal cancer within 12 cm from the anal verge, clinical stage II-III were randomly assigned to received 5-FU with radiation(RT) (FU-RT arm), or receive mFOLFOX6 with RT (FOLFOX-RT arm), or receive 4-6 cycles of mFOLFOX6 alone (FOLFOX arm), peri-operative RT was allowed if needed. The primary endpoint was DFS at 3 years defined as the interval from randomization to incomplete surgical resection, locaregional or metastatic recurrence or death, whichever occurred first. Results: A total of 495 patients were randomly assigned to three arms at 1:1:1 ration. 418 patients who had available follow up and obeyed the treatment protocol, 130 in F...